This is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 years with a Type 1 diabetes mellitus (T1DM) diagnosis. within 18 months of V0. Participants will be randomized 1:1:1:1 to one of four possible…
- Investigator
- Desmond A Schatz
- Status
- Accepting Candidates
- Ages
- 8 Years - 45 Years
- Sexes
- All